Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:47:24.486Z.
Calculation as of: 2026-10-06T18:47:24.486Z.
Quote observation: 2026-10-06T18:45:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3dc852dbbee421fd1d0f2104bcbe090e37fdd8a7ae3294fdff0c13dff3b4c360
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$2.33B
EV/EBITDA Ratio
12.80x
TTM Avg
113.41x
3Y Avg
113.41x
5Y Avg
113.41x
Market Cap
$2.37B
EV/EBITDA Ratio
10.76x
TTM Avg
16.44x
3Y Avg
40.11x
5Y Avg
40.11x
Market Cap
$2.33B
EV/EBITDA Ratio
20.43x
TTM Avg
17.29x
3Y Avg
21.88x
5Y Avg
20.47x
Market Cap
$2.40B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.29B
EV/EBITDA Ratio
7.39x
TTM Avg
6.56x
3Y Avg
7.54x
5Y Avg
13.22x
Market Cap
$2.41B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.35B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.33B | 12.80x | 113.41x | 113.41x | 113.41x |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | 10.76x | 16.44x | 40.11x | 40.11x |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 20.43x | 17.29x | 21.88x | 20.47x |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.31B | N/A | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.41B | N/A | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 7.39x | 6.56x | 7.54x | 13.22x |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | N/A | N/A | N/A | N/A |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.45B | N/A | 43.52x | 24.79x | 21.77x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
